[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 463, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 59, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 2546665, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 51, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 52, "title": "Senior VP & CFO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 58, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 67, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 58, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 57, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 43, "title": "Senior VP & Chief Business Development Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.93, "open": 3.89, "dayLow": 3.83, "dayHigh": 3.93, "regularMarketPreviousClose": 3.93, "regularMarketOpen": 3.89, "regularMarketDayLow": 3.83, "regularMarketDayHigh": 3.93, "beta": 2.106, "forwardPE": -5.764706, "volume": 375867, "regularMarketVolume": 375867, "averageVolume": 1227369, "averageVolume10days": 600780, "averageDailyVolume10Day": 600780, "bid": 3.91, "ask": 3.96, "bidSize": 200, "askSize": 100, "marketCap": 1045750144, "fiftyTwoWeekLow": 2.01, "fiftyTwoWeekHigh": 7.45, "priceToSalesTrailing12Months": 99.62372, "fiftyDayAverage": 3.9924, "twoHundredDayAverage": 4.917025, "currency": "USD", "enterpriseValue": 625835264, "floatShares": 131748688, "sharesOutstanding": 266094000, "sharesShort": 12421376, "sharesShortPriorMonth": 11901308, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0467, "heldPercentInsiders": 0.18025999, "heldPercentInstitutions": 0.75968003, "shortRatio": 12.99, "shortPercentOfFloat": 0.063, "impliedSharesOutstanding": 266772992, "bookValue": 1.984, "priceToBook": 1.9758065, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -233982000, "trailingEps": -1.14, "forwardEps": -0.68, "enterpriseToRevenue": 59.62, "enterpriseToEbitda": -3.361, "52WeekChange": 0.22429907, "SandP52WeekChange": 0.24059486, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AUTL", "underlyingSymbol": "AUTL", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "firstTradeDateEpochUtc": 1529674200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "da5466ad-c9a9-3bae-a4e5-c7afee3582d0", "messageBoardId": "finmb_562879769", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.92, "targetHighPrice": 13.0, "targetLowPrice": 7.0, "targetMeanPrice": 10.4, "targetMedianPrice": 11.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 705939008, "totalCashPerShare": 2.653, "ebitda": -186211008, "totalDebt": 288684000, "quickRatio": 18.187, "currentRatio": 18.546, "totalRevenue": 10497000, "debtToEquity": 54.691, "revenuePerShare": 0.049, "returnOnAssets": -0.18497999, "returnOnEquity": -0.61804, "freeCashflow": -150120880, "operatingCashflow": -156618000, "operatingMargins": -18.39249, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-29"}]